NASDAQ$VERA
Vera Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Vera Therapeutics reported business updates and financial results
Vera Therapeutics reported positive 36-week data from the Phase 2b ORIGIN trial and initiated the Phase 3 ORIGIN 3 clinical trial of atacicept in June. The company's balance sheet is expected to fund operations to early 2026. The company reported a net loss of $20.2 million, or $0.46 per share, and cash, cash equivalents, and marketable securities of $181.0 million as of June 30, 2023.
- Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN at the 60th ERA Congress.
- Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN.
- Released positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed both statistically significant and clinically meaningful reduction in proteinuria and stabilization of estimated glomerular filtration rate (eGFR) through 36 weeks.
- Strong balance sheet with cash and marketable securities on hand and available credit expected to fund operations to early 2026.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$993K
Forward guidance
Vera Therapeutics expects to present additional data from the ongoing Phase 2b ORIGIN clinical trial in the second half of 2023 and 2024 and announce preliminary data from the pivotal ORIGIN 3 trial in the first half of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro